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Abstract
Aims/hypothesis The adiponectin signalling pathway is
largely unknown, but recently the adaptor protein contain-
ing pleckstrin homology domain, phosphotyrosine binding
domain and leucine zipper motif (APPL1), has been shown
to interact directly with adiponectin receptor (ADIPOR)1.
APPL1 is present in C2C12 myoblasts and mouse skeletal
muscle, but its presence in human skeletal muscle has not
been investigated.
Methods Samples from type 2 diabetic, and lean and non-
diabetic obese participants were analysed by: immunopre-
cipitation and western blot; HPLC-electrospray ionisation
(ESI)-mass spectrometry (MS) analysis; peak area analysis
by MS; HPLC-ESI-MS/MS/MS analysis; and RT-PCR
analysis of APPL1 mRNA.
Results Immunoprecipitation and western blot indicated a
band specific to APPL1. Tryptic digestion and HPLC-ESI-
MS analysis of whole-muscle homogenate APPL1 unam-
biguously identified APPL1 with 56% sequence coverage.
Peak area analysis by MS validated western blot results,
showing APPL1 levels to be significantly increased in type 2
diabetic and obese as compared with lean participants.
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DOI 10.1007/s00125-011-2173-xTargeted phosphopeptide analysis by HPLC-ESI-MS/MS/
MS showed that APPL1 was phosphorylated specifically on
Ser
401. APPL1 mRNA expression was significantly in-
creased in obese and type 2 diabetic participants as
compared with lean participants. After bariatric surgery in
morbidly obese participants with subsequent weight loss,
skeletal muscle APPL1 abundance was significantly re-
duced (p<0.05) in association with an increase in plasma
adiponectin (p<0.01), increased levels of ADIPOR1
(p<0.05) and increased muscle AMP-activated protein
kinase (AMPK) phosphorylation (p<0.05).
Conclusions/interpretation APPL1 abundance is signifi-
cantly higher in type 2 diabetic muscle; APPL1 is
phosphorylated in vivo on Ser
401. Improvements in hyper-
glycaemia and hypoadiponectinaemia following weight loss
are associated with reduced skeletal muscle APPL1, and
increased plasma adiponectin levels and muscle AMPK
phosphorylation.
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Abbreviations
ADIPOR Adiponectin receptor
AMPK AMP-activated protein kinase
APPL1 Adaptor protein containing pleckstrin
homology domain, phosphotyrosine
binding domain and leucine zipper motif
ESI Electrospray ionisation-mass
MS Mass spectrometry
m/z Mass:charge ratio
p38MAPK p38 Mitogen-activated protein kinase
Introduction
The adipocyte hormone, adiponectin, has recently received
much attention due to its insulin-sensitising effects on lipid
and glucose metabolism [1–3]. The molecular causes of
insulin resistance are currently unknown, but one possible
mechanism is altered or impaired adiponectin signalling.
Defects in adiponectin signalling can arise from alterations
in total adiponectin concentrations, defects in adiponectin
receptor (ADIPOR) levels or defects in intracellular
signalling molecules. Low serum concentrations of adipo-
nectin accompany insulin resistance [4] and have been
associated with disorders such as obesity [5–7], hyper-
lipidaemia [8, 9], cardiovascular disease [10] and type 2
diabetes [11]. mRNA of both ADIPORs (ADIPOR1,
ADIPOR2) is highly expressed in human skeletal muscle
[12], as opposed to mouse, where Adipor2 is most
abundantly expressed in liver and Adipor1 is predominantly
expressed in myotubes [13].
The intracellular adiponectin signalling pathway is still
largely unknown, despite the identification of two ADI-
PORs, ADIPOR1 and ADIPOR2 [13]. ADIPORs are seven
transmembrane domain receptors, but are unique from
G-protein coupled receptors due to their opposite location
of the intracellular N-terminal and the extracellular C-
terminal [13]. Insulin-resistant ob/ob mice have decreased
abundance of ADIPOR1 and ADIPOR2 [14]; but mRNA
expression of ADIPOR1 and ADIPOR2 showed no differ-
ence between healthy, lean control and obese type 2
diabetic individuals [15]. However, Jang et al. reported
that ADIPOR2 levels are significantly lower in type 2
diabetic participants than in lean controls, with ADIPOR1
following the same trend, albeit without statistical signifi-
cance [16]. ADIPOR1 and ADIPOR2 mRNA expression is
significantly decreased in normal glucose-tolerant individ-
uals with a strong family history of diabetes as compared
with those with no history of diabetes [12]. In addition,
insulin-stimulated glucose disposal is positively associated
with ADIPOR1 and ADIPOR2 expression [12]. Finally,
cultured myotubes from obese controls and obese diabetic
participants showed increased levels of ADIPOR1 relative
to lean controls under basal conditions [17]. These findings
suggest that circulating levels of adiponectin and expression
of ADIPOR genes play an important role in the regulation
of skeletal muscle insulin action.
It is unclear whether intracellular adiponectin signalling
might also be abnormal in muscle from insulin-resistant
individuals. Previous work indicates that AMP-activated
protein kinase (AMPK) and p38 mitogen-activated protein
kinase (p38MAPK) are downstream of the ADIPOR, but do
not interact directly with ADIPORs. This work also
identified the adaptor protein containing pleckstrin homology
domain, phosphotyrosine binding domain and leucine zipper
motif (APPL1) as a protein that interacts with ADIPOR1,
using the intracellular N-terminalportion of ADIPOR1 as bait
inayeasttwo-hybridscreen[18]. APPL1 is a 79 kDa protein,
which contains several distinct domains, including a pleck-
strin homology domain, a phosphotyrosine-binding domain
and a leucine zipper motif embedded in the coiled-coil
region [19]. APPL1 interacts with numerous other receptors,
including follicle-stimulating hormone receptor, EGF recep-
tor, androgen receptor and the deleted in colorectal cancer
receptor [20–23]. In addition, APPL1 interacts with compo-
nents of the insulin signalling pathway such as v-akt murine
thymoma viral oncogene homologue 2, phosphoinositide
3-kinase, regulatory subunit 1 and the p110 subunit of
phosphatidylinositol 3-kinase [19, 22]. This indicates that
APPL1 may act as a scaffold protein. Overabundance of
APPL1 increases fatty acid oxidation and glucose metabo-
lism upon adiponectin stimulation by increasing the activity
of AMPK and p38MAPK [18]. Although APPL1 does not
directly interact with AMPK, adiponectin-stimulated activity
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interaction with the ADIPOR [18].
Some [24], but not all [25], studies suggest that AMPK
protein levels and mRNA expression are not altered in
skeletal muscle of obese or type 2 diabetic patients. In light
of the evidence connecting adiponectin signalling and
AMPK activity, and given both the decreased fat oxidation
in insulin-resistant muscle and the role of APPL1 in
adiponectin signalling, we sought to determine whether
APPL1 abundance or expression is altered in insulin
resistance. To test our hypothesis, we first sought to detect
the presence of APPL1 in human skeletal muscle, using
western blot techniques and mass spectrometry (MS). We
then established a novel approach for quantifying protein
abundance using MS to detect changes between lean
control, obese control and type 2 diabetic participants. We
also performed mRNA analysis to determine whether
changes in APPL1 and ADIPOR1 were present between
these groups. Finally, we examined the effect of weight loss
following bariatric surgery on skeletal muscle ADIPOR1/2,
APPL1 and AMPK phosphorylation in obese insulin-
resistant individuals.
Methods
Participants for protein analysis We recruited 29 partici-
pants for protein abundance and quantification studies.
These included lean control participants, obese control
participants and type 2 diabetic participants (Table 1). All
studies were approved by the Institutional Review Board of
the University of Texas Health Science Center at San
Antonio or Arizona State University. Results for some
participants used in this study have been published
previously [26].
Participants for mRNA analysis Muscle (vastus lateralis)
biopsies from 21 participants were used for real-time
quantitative PCR analysis. Participant categories were lean
control, obese control and type 2 diabetic (Table 2). The
study protocol was approved by the Institutional Review
Board of University of Texas Health Science Center at San
Antonio. All participants gave written informed consent.
Effects of weight loss on adiponectin signalling We also
studied six (age 38±4 years, BMI 48.5±4.8 kg/m
2, HbA1c
6.0±0.1% [mean±SEM]) non-diabetic morbidly obese
participants with the metabolic syndrome, who underwent
bariatric surgery (Roux-en-Y gastric bypass) (Table 3).
Vastus lateralis muscle biopsies were obtained during
surgery and 6 months following surgery, and were used
for real-time quantitative PCR analysis and determination
of AMPK phosphorylation. These studies were approved
by the Baylor College of Medicine Institutional Review
Board.
Oral glucose tolerance test Baseline blood samples for
determining plasma glucose, NEFA and insulin concen-
trations were drawn at −30, −15 and 0 min. At time 0,
participants ingested 75 g glucose in 300 ml water. Plasma
glucose, NEFA and insulin concentrations were measured
at 15 min intervals for 2 h.
Euglycaemic–hyperinsulinaemic clamp with muscle biop-
sies A euglycaemic–hyperinsulinaemic clamp was per-
formed to determine insulin sensitivity and to obtain
human skeletal muscle biopsy as previously described
[27]. Basal biopsies were used for all protein abundance
and MS analyses. A clamp was completed to determine
participants’ insulin sensitivity.
Analytical determinations Plasma glucose was measured
using the glucose oxidase method (Beckman Instruments,
Fullerton, CA, USA). Plasma insulin concentrations were
measured by radioimmunoassay (Diagnostic Products, Los
Angeles, CA, USA). Plasma adiponectin concentration was
measured by ELISA (Linco Research, St Charles, MO,
USA)
Muscle biopsy processing Frozen muscle biopsies were
homogenised in detergent containing lysis buffer as
described [28]. Briefly, muscle biopsies were homogenised
Characteristic Lean control Obese control Type 2 diabetes
Age (years) 36±3 41±3 48±2*
Women (n)4 4 5
Men (n)6 5 5
BMI (kg/m
2) 25.8±1.0 31.6±0.9 31.8±2.4
Fasting glucose (mmol/l) 5.5±0.2 5.4±0.1 8.9±1.3†
Lean participants (%) 76.2±2.3 67.3±2.8 64.2±3.3*
HbA1c (%) 4.8±0.1 5.0±0.1 7.6±0.8‡
M value (mg kg
−1 min
−1) 6.7±0.6 4.1±0.4 1.9±0.7***
Table 1 Characteristics of
participants used for protein
analysis
Values are given as mean±SEM,
unless indicated otherwise
*p<0.05 and ***p<0.0001 vs
lean control;
†p<0.005 vs lean
and obese control;
‡p<0.0005
vs lean and obese control
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(final concentrations): 50 mmol/l HEPES, pH 7.6,
150 mmol/l NaCl, 20 mmol/l sodium pyrophosphate,
20 mmol/l β-glycerophosphate, 10 mmol/l NaF, 2 mmol/l
sodiumorthovanadate,2mmol/lEDTA,pH8.0,1%(vol./vol.)
IGEPAL, 10% (vol./vol.) glycerol, 2 mmol/l phenyl-
methylsulfonyl fluoride, 1 mmol/l MgCl2, 1 mmol/l CaCl,
10 μg/ml leupeptin and 10 μg/ml aprotinin. Biopsies were
homogenised with a polytron homogeniser for 20 s, cooled
on ice for 30 min and then centrifuged for 20 min at
10,000 g and 4°C. Biopsy supernatant fractions were
frozen until use. Protein concentrations were determined
using the Lowry method [29].
Immunoprecipitation, gel electrophoresis and western blot
analysis APPL1 was immunoprecipitated using an anti-
APPL1 antibody (gift from L. Q. Dong). Protein A
sepharose beads (Sigma, St Louis, MO, USA) were
rehydrated for 2 h at 4°C in 1× PBS (Gibco, Grand Island,
NY, USA). Beads were distributed equally between
samples, washed three times in PBS and then incubated
for 1 h at room temperature in 300 μl PBS with anti-APPL1
antibody (2 μl). Beads were again washed three times with
PBS and aspirated till dry. Muscle lysates (2.5 mg) were
added to beads and incubated overnight at 4°C. After
incubation, lysates were removed and the beads washed
three times with PBS, after which 35 μl 2× SDS was added
to beads and the beads boiled at 95°C for 4 min. Protein
(immunoprecipitated or whole muscle lysate) was separated
on a 10% SDS-polyacrylamide gel, transferred onto a
nitrocellulose membrane and blocked for 1 h in 1% (wt/
vol.) BSA at room temperature. Membranes were incubated
for 1 h at room temperature with anti-APPL1 or anti-
β-actin (Cell Signaling Technology, Danvers, MA, USA)
primary antibodies. Membranes were washed three times
and incubated for 1 h at room temperature with secondary
antibodies (anti-rabbit, 1:1500; GE Healthcare, Piscataway,
NJ, USA). Membranes were then washed and proteins
visualised using an electrochemoluminscence reaction
(Perkin Elmer, Boston, MA, USA). The densities of the
bands corresponding to the proteins of interest were
measured using a software package (Quantity One, Versa-
doc; Bio-Rad, Hercules, CA, USA). The ratio of the
densities of APPL1 to β-actin was analysed by one-way
ANOVA. Significance was defined as p<0.05.
Antibodies The APPL1 antibody was raised in rabbits as
previously described [18]. Briefly, antiserum to APPL1 was
raised in rabbits using a glutathione-S-tranferase-APPL1c.
An antibody to β-actin was purchased from Cell Signaling.
Electrophoresis, staining and in-gel digestion Proteins
were separated on a 10% SDS-polyacrylamide gel contain-
ing 100 μg of muscle lysate per participant. Proteins were
visualised with Coomassie blue staining. The gel portions
containing APPL1 (80–90 kDa) and actin (37–50 kDa)
were excised and prepared as previously described [28, 30],
and as outlined in the electronic supplementary material
(ESM, Preparation of samples).
Mass spectrometry HPLC-electrospray ionisation (ESI)-
MS was performed on a hybrid linear ion trap Fourier
transform ion cyclotron resonance mass spectrometer (LTQ
FT; Thermo Fisher, San Jose, CA, USA), which was fitted
with a PicoView nanospray source (New Objective,
Woburn, MA, USA). The mass spectrometer was calibrated
weekly according to manufacturer’s instructions, achieving
Characteristic Lean control Obese control Type 2 diabetes
Age (years) 32±3 34±3 50±4†
Women (n)3 3 3
Men (n)4 4 4
BMI (kg/m
2) 24.2±1.0 29.3±1.0 34.1±3.3*
Fasting glucose (mmol/l) 5.1±0.2 5.2±0.1 7.2±0.7†
Lean participants (%) 81.6±6.9 69.2±2.6 70.5±3.1
HbA1c (%) 4.7±0.1 5.1±0.1 6.9±0.4†
M value (mg kg
−1 min
−1) 6.3±0.5 4.1±0.6* 2.7±0.5***
Table 2 Characteristics of
participants used for mRNA
analysis
Values are given as mean±SEM,
unless indicated otherwise
*p<0.05 and ***p<0.001 vs
lean control;
†p<0.005 vs lean
and obese control
Table 3 Metabolic and anthropometric variables before and after
weight loss subsequent to bariatric surgery
Variable Before weight loss After weight lost
Body weight (kg) 135.2±13.8 100.3±10.1**
BMI (kg/m
2) 48.5±4.8 35.1±2.9**
Fasting insulin (pmol/l) 161.8±10.4 84.7±6.3**
Fasting glucose (mmol/l) 5.8±0.3 4.7±0.1**
HOMA-IR 6.0±0.5 2.6±0.2**
Adiponectin (μg/ml) 6.5±0.6 11.6±0.9**
Values are given as mean±SEM
**p<0.01 for difference between before vs after weight loss
HOMA-IR, HOMA of insulin resistance
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capillary HPLC was performed using a device (Paradigm
MS4 micro HPLC; Michrom BioResources, Auburn, CA,
USA) with a PicoFrit column (New Objective) (75 μmol/l
i.d.; packed with ProteoPep II C18 material, 30 nm), mobile
phase linear gradient of 2 to 27% (vol./vol.) acetonitrile
in 0.1% (vol./vol.) formic acid in 45 min, a hold of 5 min
at 27% acetonitrile, followed by a step to 50% acetonitrile,
a hold of 5 min and then a step to 80% (flow rate
250 nl/min).
A ‘top ten’ approach was used to identify APPL1 in
muscle homogenate, whereas a ‘targeted’ approach was
used for peak area analysis; both of these methods have
been described and validated previously by our lab [28, 31].
The ‘top ten’ approach was used for immunoprecipitated
APPL1 from human skeletal muscle and to verify the
accuracy of the antibody. All further experiments for MS
analysis were performed on whole-muscle homogenates.
Peak area analysis was used to determine differences in
protein levels between the three participant groups studied.
To validate western blot data and mRNA data, β-actin was
used as a normalisation protein for APPL1 levels; peptides
targeted are listed in ESM Table 1. We reconstructed ion
chromatograms of the fragment ions of seven peptides for
APPL1 and β-actin quantification. The mass:charge ratio
(m/z) values of the seven representative peptides were
placed on the target list, based on ion intensity. The
fragment ion m/z values had to be higher than the precursor
ion in order to reduce interference from the background or
other co-eluting peptide ions. We assessed the linearity of
the β-actin to APPL1 normalisation quantification; com-
plete methods for this can be found in the ESM (Validation
of the use of the APPL1). This method demonstrates that
our choice of β-actin as an internal normalisation peptide is
valid for protein quantification using the peak area
technique. Once these data were generated, 100 μgo f
whole-muscle homogenate was run on a gel, and bands for
APPL1 and β-actin were excised, trypsinised, desalted and
analysed by MS as described above. The ratios of
APPL1:β-actin were used for our quantification analysis.
Real-time quantitative RT-PCR Total RNA was isolated
using STAT-60 (Tel-Test, Friendswood, TX, USA) and
purified with an mRNA kit (Qiagen, Valencia, CA, USA)
according to the manufacturer’s instructions. Concentration
was determined by spectrophotometer at 260/280 nm.
Quantitative real-time PCR was used to quantify mRNA.
The specific primers used for quantification are listed in
ESM Table 2. mRNA fold changes were calculated relative
to the average lean control value quantified relative to
β-actin. A device (ICycler; Bio-Rad) was used to quantify
mRNA levels and fold changes were expressed using the
2ΔΔCtmethod [32].
AMPK phosphorylation For western blotting, muscle
lysates were prepared as previously described. Proteins
(50 μg) from muscle lysates were separated by 10% SDS-
PAGE and transferred to nitrocellulose membranes. After
blocking the membranes with 5% (wt/vol.) BSA/TBST,
membranes were probed overnight at 4°C with antibodies
against anti-phospho-AMPK (Thr172) (1:1,000; Cell Sig-
naling). AMPK phosphorylation was normalised for total
AMPK α protein content using a pan-α antibody (1:1000;
Upstate Biotechnology, Lake Placid, NY, USA). Bound
antibodies were detected using anti-rabbit immunoglobulin
horseradish-peroxidase-linked antibody and electrochemo-
luminscence reagents (Perkin Elmer), and the bands were
quantified using ImageQuant (GE Healthcare, Piscataway,
NJ, USA) software.
Statistical analysis Changes in APPL1 using western blot
and MS were analysed by ANOVA. Changes in mRNA
expression are expressed as fold change relative to lean
control average and statistical significance compared with
lean control assessed by ANOVA. Changes after weight
loss in obese participants were compared using paired
t tests. All data are presented as means±SEM. A value of
p<0.05 was considered statistically significant.
Results
APPL1 protein abundance determined by western blot-
ting The detection of APPL1 in human skeletal muscle by
immunoprecipitation indicates that measurable quantities of
the protein were available for analysis (ESM Fig. 1).
Whole-muscle homogenates (not immunoprecipitated) were
separated by SDS-PAGE and western blots analysed for
densitometry. APPL1 and actin antibodies showed specific
bands for the corresponding molecular weights of APPL1
and β-actin. APPL1 protein levels were significantly
increased in type 2 diabetic participants (2.42±0.25
arbitrary units [means±SEM]) as compared with lean
control (1.78±0.18) and obese control participants
(1.74±0.12; p<0.05 for all) (Fig. 1a, b). Our attempts to
co-immunoprecipate endogenous ADIPORs from human
skeletal muscle were unsuccessful. Undetectability of co-
immunoprecipitation may only mean that the interaction
was too weak to be maintained during the immunoprecipi-
tation procedure. Although previous investigators have
reported co-immunoprecipation of APPL1 and ADIPORs,
this was done in a cell-based system [18]. This is not
uncommon, as strong co-immunoprecipitation of the insulin
receptor and IRS1 in a yeast two-hybrid system has also
been reported, but this interaction is very difficult to
observe in human skeletal muscle (L. J. Mandarino,
unpublished results) [33].
2126 Diabetologia (2011) 54:2122–2131APPL1 quantification using peak area analysis Validation
of APPL1 quantification using MS is shown in ESM Fig. 2,
with complete methods for APPL1 identification described
in the ESM (APPL1 identification). To confirm changes of
APPL1 levels as visualised by western blots, HPLC-ESI-
MS analysis of muscle homogenates was performed. A
‘targeted’ approach using peptide m/z values for each
APPL1 and β-actin peptide was performed. Seven unique
peptides for APPL1 or β-actin were targeted. Those
identified were quantified ±95% CI. ESM Fig. 3 shows
one of seven peptides used for APPL1 quantification as an
example. The peak area is calculated for the unique
spectrum identified as the particular peptide targeted. Peak
area was obtained for β-actin and APPL1 peptides, and the
ratio of APPL1:β-actin was used to numerically evaluate
protein amount in the sample. Peak area analysis of APPL1
protein showed significantly higher levels in obese control
and type 2 diabetic participants than in lean control
participants (Fig. 1c).
Identification of phosphorylation of APPL1 at Ser
401 in
human muscle We had previously identified Ser
430 and
Ser
401 as APPL1 phosphorylation sites in cultured myo-
cytes (L. Q. Dong, unpublished data). In addition, previous
reports have identified Ser
401 as a phosphorylation site on
APPL1 in HeLa nuclear extracts [34]. Since phosphoryla-
tion was undetectable using the phospho-specific antibodies
developed for that study, we used MS to assess phosphory-
lation of APPL1. We targeted these and other potential
phosphorylation sites as predicted by Phosphosite (www.
phosphosite.org; accessed 13 April 2011), calculated as a
loss of 80 Da or 98 Da on the basis of a 2+ or 3+ charge
state, respectively. Due to the low levels of APPL1
phosphorylated peptides in whole-muscle homogenates,
immunoprecipitation of APPL1 was performed. Muscle
homogenate (2.5 mg) was immunoprecipitated with the
APPL1 antibody, and phospho-Ser
401 targeted and identi-
fied on the basis of the 3+ charge state. The tandem mass
spectrum of pSer
401 peptide is shown in Fig. 2.
Changes in APPL1 and ADIPOR1 mRNA expression
between participant groups To determine whether changes
in mRNA expression of APPL1 and ADIPOR1 were present
in lean, obese and diabetic participants, real-time PCR was
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Fig. 1 Human skeletal muscle APPL1 protein level changes. a Vastus
lateralis muscle biopsies were homogenised, separated by SDS-PAGE
and proteins transferred electrophorectically to nitrocellulose mem-
brane. Membranes were exposed to anti-APPL1 or β-actin antibody
and visualised by chemiluminescence. Density of each band was
determined using Versadoc software. b Protein quantification,
expressed as ratio of APPL1:β-actin, showing that APPL1 levels
increased significantly in type 2 diabetic participants as compared
with lean control and obese control participants. Values mean
±SEM (error bars). c Whole skeletal muscle homogenates were
used for peak area analysis. Biopsies were homogenised, separated
by SDS-PAGE and stained with Coomassie blue. Bands were cut
for APPL1 and β-actin, subjected to trypsin digestion and
quantified by MS as described. Protein levels are expressed as
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2). Values are mean±SEM (error bars);
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Diabetologia (2011) 54:2122–2131 2127used. Results indicate a similar trend to that seen in protein
levels of APPL1. Obese controls and type 2 diabetic
patients had significantly increased mRNA expression of
APPL1 compared with lean controls (Fig. 3a). Skeletal
muscle ADIPOR1 expression increased approximately
threefold (p<0.05) in obese participants compared with
lean controls, although type 2 diabetic patients did not
differ from lean control individuals (Fig. 3b).
Changes in skeletal muscle adiponectin signalling after
weight loss At 6 months following Roux-en-Y gastric
bypass surgery [35], body weight (p<0.01), mean fasting
plasma glucose (p<0.01), plasma insulin (p<0.01) and
insulin resistance (HOMA of insulin resistance) (p<0.01)
decreased significantly (Table 3). The improvement in
insulin sensitivity was associated with an increase in
plasma adiponectin levels (6.5±0.6 to 11.6±0.9 μg/ml,
p<0.01). Skeletal muscle ADIPOR1 and ADIPOR2 expres-
sion increased approximately twofold (p<0.05), while
APPL1 expression decreased by approximately 50%
(p<0.05) following weight loss (Fig. 4). Skeletal muscle
AMPK phosphorylation (P-AMPK: AMPK ratio) increased
significantly following weight loss (0.47±0.05 to 0.78±0.13,
p<0.05) (Fig. 5).
Discussion
Adiponectin signalling is an intriguing area of research due
to its anti-inflammatory, glucose-lowering and insulin-
sensitising properties [1–3, 36–38]. Although some compo-
nents of the pathway have been elucidated, many questions
regarding the regulation and interaction of proteins
involved remain unanswered. Previous findings have
shown that adiponectin interacts with the C-terminal
extracellular portion of the ADIPOR [13]a n d ,u p o n
binding, recruits APPL1 to the N-terminal intracellular
portion [18]. This binding may facilitate the downstream
effects of adiponectin, which include AMPK and
p38MAPK activation, thus leading to increased fatty acid
oxidation and glucose uptake [18, 37].
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(P-AMPK):total AMPK ratio in six morbidly obese patients before
(pre) and after (post) weight loss following bariatric surgery.
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Fig. 4 Effect of weight loss following bariatric surgery on ADIPOR1,
ADIPOR2 and APPL1 expression. Quantitative real-time PCR was
used to quantify mRNA. mRNA fold changes were calculated relative
to average pre-surgery value quantified relative to 18S values. mRNA
expression and fold changes are expressed using the 2ΔΔCtmethod
[32]. *p<0.05
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Fig. 3 Human skeletal muscle expression of (a) APPL1 and
(b) ADIPOR1. Quantitative real-time PCR was used to quantify mRNA.
mRNA fold changes were calculated relative to average lean control
value quantified relative to β-actin. mRNA expression and fold changes
are expressed using the 2ΔΔCtmethod [32]. *p<0.05 vs lean
2128 Diabetologia (2011) 54:2122–2131Previous reports have indicated that APPL1 plays an
important role in the adiponectin signalling pathway by
transmitting signals from the receptor to downstream targets
[18, 19]. Although APPL1 has been identified and
characterised in cells, to date no studies have identified its
presence in human skeletal muscle. Here we have identified
APPL1 in biopsies taken from human vastus lateralis
muscle and quantified APPL1 protein and mRNA in
samples from lean, obese and type 2 diabetic participants.
To determine whether APPL1 was present in human
skeletal muscle, immunoprecipitated and supernatant frac-
tions of muscle homogenates were run on western blots,
revealing a band specific for APPL1. To verify that this
band was indeed APPL1, we ran identical gels, using one
for western blot and the other for Coomassie staining. The
Coomassie stain showed a very light band at ~80 kDa,
similar to the size of APPL1 (82 kDa). We cut this band and
performed a ‘top ten’ approach using the MASCOT
(version 2.2; Matrix Science, London UK) search engine,
which detects the top ten most abundant proteins in a
sample. MASCOT detected APPL1 in the muscle homog-
enate sample with sequence coverage of 56%. We also
tested whether APPL2 was present in the sample, but did
not find this protein (data not shown). Upon verification
that the western blot band corresponded to APPL1, we ran
whole-muscle homogenates to quantify western blots using
the APPL1 antibody. Western blot quantification showed
APPL1 levels to be significantly higher in type 2 diabetic
patients than in lean and obese controls.
Although western blot can be useful for quantifying
protein levels, we validated our APPL1 quantification
results using MS. In fact, in the present study, we
implemented a unique MS quantification technique using
β-actin peptides as normalisation factor. To verify the
validity of this method for quantification purposes, increas-
ing amounts of muscle homogenate samples were analysed
(50 μg, 75 μg and 100 μg). Peptides for β-actin and
APPL1 were targeted and Scaffold (version 02_00_06;
Proteome Software, Portland, OR, USA) was used to
quantify peak areas. The peak areas of the peptides for
each protein were averaged and plotted for regression
analysis. The averages of the peptides were quantified so
that the ratio of APPL1:β-actin levels represented protein
present in the sample. The CV from these ratios was found
to be 6.59%, indicating that increasing amounts of sample
were consistent based on the APPL1:β-actin ratio. For this
study, we quantified proteins based on peak area as
opposed to ion intensity, because peak area is the average
peak of many scans, as opposed to using just one scan for
ion intensity, and therefore reduces variability.
After determining that β-actin could be used as a
normalisation factor, we then quantified APPL1 levels in
human skeletal muscle samples using peak area analysis.
The peak area ratio showed significantly higherAPPL1 levels
in obese control and type 2 diabetic participants compared
with lean control. The difference in data between western blot
and MS could be explained by the variability in immunoblot
analysis. Due to the mRNA and MS data, and also based on
linearity validation, we believe that MS analysis of protein
abundance is more likely to be correct. This indicates that
APPL1 levels are higher in an insulin-resistant state (obese
controlsandtype2diabeticpatients)andthatthebodymaybe
compensating for decreased levels of adiponectin, and
therefore trying to increase signalling downstream of the
ADIPOR through increased APPL1 production.
We also used quantitative real-time PCR to determine
changes in APPL1 mRNA among the three experimental
groups. APPL1 mRNA increased significantly in obese
control and type 2 diabetic participants, as compared with
lean control. This verifies our protein data, showing that in
a state of insulin resistance, APPL1 mRNA expressison is
increased, possibly representing a compensatory mecha-
nism in skeletal muscle to enhance adiponectin signalling.
Additionally, ADIPOR1 mRNA expression was significant-
ly increased in obese compared with lean controls, but was
not altered in type 2 diabetic patients. The increase in
ADIPOR1 mRNA in obese controls may be an additional
compensatory mechanism triggered by the decreased
adiponectin levels in obese and type 2 diabetic patients.
ADIPOR1 mRNA expression in type 2 diabetic patients
may become exhausted, thus leading to levels similar to
those in lean controls. The combination of compensatory
mechanisms for APPL1 and ADIPOR1 due to decreased
adiponectin levels in the obese state illustrates how this
signalling pathway is altered in insulin resistance (Fig. 6).
To further understand how APPL1 and ADIPORs
change in relation to insulin resistance, skeletal muscle
ADIPOR1/2 and APPL1 expression was determined fol-
lowing weight loss after bariatric surgery in morbidly
obese, non-diabetic participants with the metabolic syn-
drome. Following weight loss, plasma adiponectin in-
creased significantly and was associated with a twofold
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Fig. 6 Schematic representation of protein or mRNA changes in
adiponectin, ADIPOR1/2 and APPL1 associated with obesity, diabetes
and post weight loss.
aCompensatory mechanism compared with lean;
bexhausted system compared with lean;
cnormalised system compared
with pre-weight loss
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APPL1 expression was significantly reduced and skeletal
muscle AMPK phosphorylation increased significantly,
suggesting that the correction of hyperglycaemia and
hypoadiponectinaemia following weight loss is associated
with a reduction in APPL1 expression. This normalisation
of APPL1 and ADIPOR1/R2 levels after weight loss
illustrates the compensatory mechanism to changes in
adiponectin levels pre and post-surgery (Fig. 6).
In addition to mRNA and protein level changes, we also
have identified Ser
401 as a phosphorylation site in APPL1
in human skeletal muscle. This phosphorylation site has
previously been identified in HeLa cell nuclear extract,
although this is the first time it has been reported in human
skeletal muscle [34]. Currently, we are testing the kinase
responsible for this phosphorylation site, and whether this
site plays a functional role in regulating APPL1 function in
adiponectin signalling.
In conclusion, APPL1 levels are associated with insulin
resistance, during which the body may be attempting to
compensate for the decreased adiponectin levels found in
this state. In addition, APPL1 is phosphorylated in human
skeletal muscle at Ser
401, a mechanism of functional
regulation that is now under investigation and may shed
new light on the adiponectin signalling pathway. Improve-
ments in hyperglycaemia and hypoadiponectinaemia follow-
ing weight loss are associated with enhanced skeletal muscle
adiponectin signalling, as well as AMPK phosphorylation
and a reduction in APPL1 levels.
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